Clinic for Internal Medicine II, University Medical Centre, Regensburg, Germany.
J Atheroscler Thromb. 2012;19(6):539-51. doi: 10.5551/jat.10918. Epub 2012 Apr 4.
In subjects with metabolic syndrome (MetS) endothelial dysfunction is a very consistent finding. Processes leading to endothelial dysfunction and atherosclerosis involve the altered control of subclinical inflammation by innate immune defenses that possibly include mannose-binding lectin (MBL). We investigated the associations of MBL with traits of MetS and early atherosclerosis in obese subjects before and after marked weight reduction.
In a prospective longitudinal study, MBL concentrations of 96 severely obese subjects with and without MetS (Ø BMI with MetS 41.0±7.9 kg/m(2), Ø BMI without MetS 39.4±7.7 kg/m(2) were examined in association with markers of insulin resistance, dyslipidemia, adipokines, and subclinical atherosclerosis before and after marked weight loss (Ø weight loss 20±8 kg after 3 months of participation in a standardized weight reduction program), in addition to the study of 25 seemingly healthy lean subjects (BMI 20-25 kg/m(2).
MBL concentrations did not differ between healthy lean and severely obese subjects independently of the presence of metabolic abnormalities. In severely obese subjects there was no significant difference concerning the cardiovascular risk profile, apolipoproteins, inflammatory and metabolic parameters, and markers of endothelial dysfunction and atherosclerosis between subjects with functional MBL deficienct (MBL<778 ng/mL) and MBL sufficient (MBL≥778 ng/mL) obesity. Marked weight loss did not influence MBL levels.
Our findings suggest that plasma levels of MBL did not differ between healthy lean and severely obese subjects. MBL did not affect cardiovascular risk factors, or markers of endothelial dysfunction and early atherosclerosis in severely obese patients before and after marked weight loss.
在代谢综合征（MetS）患者中，内皮功能障碍是一个非常一致的发现。导致内皮功能障碍和动脉粥样硬化的过程涉及到固有免疫防御对亚临床炎症的控制改变，其中可能包括甘露糖结合凝集素（MBL）。我们研究了 MBL 与肥胖患者代谢综合征和早期动脉粥样硬化特征的相关性，这些患者在明显体重减轻前后都有 MBL。
在一项前瞻性纵向研究中，我们检测了 96 名严重肥胖患者（有或无 MetS，Ø BMI 伴 MetS 为 41.0±7.9kg/m(2)，Ø BMI 无 MetS 为 39.4±7.7kg/m(2)）和 25 名看似健康的瘦人（BMI 为 20-25kg/m(2)）的 MBL 浓度与胰岛素抵抗、血脂异常、脂肪因子和亚临床动脉粥样硬化的标志物有关，这些标志物在明显体重减轻（参加标准化减肥计划 3 个月后，体重减轻 20±8kg）前后都有检查。
MBL 浓度在健康瘦人和严重肥胖患者之间没有差异，无论是否存在代谢异常。在严重肥胖患者中，MBL 缺乏（MBL<778ng/mL）和 MBL 充足（MBL≥778ng/mL）肥胖患者之间，心血管风险状况、载脂蛋白、炎症和代谢参数以及内皮功能障碍和动脉粥样硬化标志物之间没有显著差异。明显体重减轻并不影响 MBL 水平。
我们的研究结果表明，健康瘦人和严重肥胖患者之间的 MBL 血浆水平没有差异。MBL 对严重肥胖患者明显体重减轻前后的心血管危险因素或内皮功能障碍和早期动脉粥样硬化标志物没有影响。
